StreetAlpha.app
Home › Stocks › QURE

uniQure N.V. (QURE)

Healthcare
$19.35
▼ −4.35%
LAST CLOSE · NOV 20

uniQure develops gene therapies for rare and serious diseases, including Huntington's disease and Fabry disease. It last closed at $19.35 on Nov 20, down 4.35% on the day. The next earnings report for QURE is expected around Mon, Mar 1, 2027. For the quarter ended Sep 2026, QURE reported EPS of -$0.88 on revenue of $5.2M, with revenue up 40.4% from a year ago. Over its last 8 reports the stock moved an average of 8.8% the session after earnings. Over the last 12 months QURE insiders bought $0 of stock on the open market and sold $20.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is QURE in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold QURE.

Key Stats

Last 12 months
Results
Revenue
$20.2M
+28.0% vs a year ago
Net income
−$232.9M
−1154.8% margin
EPS (diluted)
−$3.51
Free cash flow
−$193.0M
−956.8% margin
Valuation
Market cap
$1.4B
70.1M shares
P/E
–
No P/E while losing money
Price to sales
67.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$98.4M
At Sep 30
Debt
$50.3M
At Sep 30
Shareholder equity
$294.7M
Shares outstanding
70.1M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $524.0M$524.0MFY2021FY2022: $106.5M$106.5MFY2022FY2023: $15.8M$15.8MFY2023FY2024: $27.1M$27.1MFY2024FY2025: $16.1M$16.1MFY2025

From QURE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Mar 1
Estimated date · Time not announced
Reported EPS
-$0.88
Quarter ended Sep 2026
Year ago EPS
-$1.38
Same quarter last year
Revenue
$5.2M
+40.4% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.50Dec '24Mar 2025: -$0.82Mar '25Jun 2025: -$0.69Jun '25Sep 2025: -$1.38Sep '25Dec 2025: -$0.56Dec '25Mar 2026: -$0.85Mar '26Jun 2026: -$1.22Jun '26Sep 2026: -$0.88Sep '26Latest -$0.88
Revenue by quarter
Dec 2024: $5.2MDec '24Mar 2025: $1.6MMar '25Jun 2025: $5.3MJun '25Sep 2025: $3.7MSep '25Dec 2025: $5.6MDec '25Mar 2026: $3.6MMar '26Jun 2026: $5.8MJun '26Sep 2026: $5.2MSep '26Latest $5.2M
How QURE moved after its last 8 reports
Average move the session after a report ±8.8%
Nov 4, 2026Time not announced−3.5%
Jul 29, 2026Time not announced+9.3%
May 5, 2026Time not announced+2.3%
Mar 2, 2026Time not announced−32.8%
Nov 10, 2025Time not announced−5.9%
Jul 29, 2025Time not announced−8.7%
May 9, 2025Time not announced+4.4%
Feb 27, 2025Time not announced+3.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on QUREStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on QURE
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on QURE

Technical Analysis

QURE · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 17% below its 20 day and 40% below its 50 day average. It is 53% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 33), near oversold. The nearest support is the Pivot S1 at $18.37, and the nearest resistance the Pivot at $19.98.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 9.4%/day
Key levels
$51.7252 week high+167.3%
$35.68100 day average+84.4%
$29.52200 day average+52.6%
$27.0550 day average+39.8%
$26.20Swing high (Nov 12)+35.4%
$22.7320 day average+17.5%
$20.97Pivot R1+8.4%
$19.98Pivot+3.3%
$19.35Last close
$18.37Pivot S1−5.1%
$8.7352 week low−54.9%
Indicators
RSI (14)32.66Weak, oversold below 30Neutral
MACD-1.65Below its signal lineBearish
Stochastic3.3Near the bottom of its rangeOversold
ADX (14)22.2Weak trend
Williams %R-95.1Oversold below −80, overbought above −20Oversold
CCI (20)-140.6Oversold below −100, overbought above 100Oversold
Rate of change−10.8%Change over 10 sessionsBearish
ATR (14)$1.82Typical daily range, 9.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for QURE

What happened before

See how QURE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow QURE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How QURE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for QUREHow many large options trades hit QURE, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

QURE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ●137 buying vs 125 selling
  • ▼Held by funds -9.1 pts
  • ▼Funds holding -14
  • ▼Superinvestors: 0 added, 3 cut
  • ▼Put/call 0.20 to 0.37
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding243257−5.4%
In funds' top 1036−50.0%
Held by funds85.8%95.0%−9.1 pts
New / increased44 / 9389 / 87−22.2%
Reduced / sold out67 / 5860 / 50+13.6%
Put/call ratio0.370.20+87.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See QURE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

QURE Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$20.2M33 sales · 12 insiders
89% of the selling was under pre-arranged trading plans.
2026-01 sold $805K2026-02 sold $444K2026-03 sold $848K2026-05 sold $1.1M2026-06 sold $15.9M2026-07 sold $952K2026-11 sold $193KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 6David D. MeekDirectorSale plan9,080$21.25$193K
Jul 2Matthew C KapustaCEO, Managing DirectorSale plan21,082$45.16$952K
Jun 30Jack KayeDirectorSale plan21,167$46.44$983K
Jun 30Walid Abi-SaabChief Medical OfficerSale plan30,000$46.42$1.4M
Jun 26Walid Abi-SaabChief Medical OfficerSale1,434$46.86$67K
Jun 25Matthew C KapustaCEO, Managing DirectorSale plan35,412$50.02$1.8M
Every insider buy and sale for QURE over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See QURE insider trades →

From SEC Form 4 filings by QURE's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QURE is in one of them and how their past QURE trades turned out.

QURE in the AI portfolios
Loading…

QURE News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered QURE in an article yet. Here's the latest on the wider market.

QURE in the news

About uniQure N.V.

uniQure is a gene therapy company based in Amsterdam. It develops treatments meant to be given as a single dose to patients with rare and other serious diseases. Its clinical programs target Huntington's disease, temporal lobe epilepsy, Fabry disease, and a form of amyotrophic lateral sclerosis linked to SOD1 gene mutations. These candidates are still in clinical development and have not yet been approved for sale.

Headquarters
Amsterdam